patients in checkmate 067 demonstrate durable complete responses
Published 4 years ago • 277 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
1:33
dr. wolchok on the safety profile in checkmate-067 in melanoma
-
3:47
checkmate 067: a phase iii trial of nivolumab combined with ipilimumab
-
0:59
checkmate 067: phase 3 trial of nivolumab in melanoma
-
2:48
checkmate067 outcomes: nivolumab plus ipilimumab in advanced melanoma
-
19:25
melanoma review for the absite - questions and answers
-
8:14
immune therapy: future game changers in prostate cancer | ask a prostate expert, mark scholz, md
-
2:44
cancer immunotherapy with nivolumab plus ipilimumab vs. chemotherapy: insights from checkmate 227
-
3:45
update on checkmate 067, an advanced melanoma clinical trial
-
3:59
checkmate 067 - combined nivolumab and ipilimumab
-
3:05
phase 3 checkmate 067 trial of nivolumab in previously untreated advanced melanoma
-
2:31
dr. wolchok on updated checkmate-067 results for melanoma
-
1:56
checkmate 067: combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
1:55
investigating responses to nivolumab and ipilimumab in advanced rcc
-
3:30
achieving durable responses in advanced melanoma
-
2:01
checkmate 9er trial demonstrates efficacy in patients with rcc
-
0:58
combination nivolumab and ipilimumab shows efficacy in advanced melanoma
-
12:48
checkmate 214: 4-year follow-up and subgroup analysis of patients without nephrectomy
-
25:50
melanoma | 2022 oneoncology conference
-
20:35
hitting the mark with targeted therapy: braf, nras, ckit, etc...sullivan
-
1:49
the significance of the ipilimumab/nivolumab findings in melanoma
-
0:49
scandium 2: ihp with ipilimumab and nivolumab in uveal melanoma metastases
-
0:50
checkmate 227 induced manageable toxicities with immunotherapy combination in nsclc